Randomized Trialhigh evidence
Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression: A Randomized Clinical Trial.
JAMA·October 26, 2026·PMID 42931733
Why it mattersTreatment-resistant depression often requires prolonged in-clinic monitoring with psychedelics like psilocybin or repeated visits for esketamine. Intranasal mebufotenin offers a rapid, short-acting psychedelic experience with a 2-hour discharge window, potentially improving access and convenience for patients and clinics.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled